Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.

  title={Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.},
  author={Jordon M Inkol and Samuel E. Hocker and Anthony J. Mutsaers},
  journal={PloS one},
  volume={16 8},
BACKGROUND Canine urothelial carcinoma is the most common form of canine bladder cancer. Treatment with chemotherapy has variable response rates leading to most dogs succumbing to their disease within a year. Cannabidiol is an emerging treatment within the field of oncology. In reported in vivo studies, cannabidiol has induced apoptosis, reduced cell migration, and acted as a chemotherapy sensitizer in various human tumor types. The aim of this study was to characterize the effects of… 

Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway

This was the first study elucidating the underlying molecular mechanism of CBD in inhibiting EMT and metastasis via the Wnt/β-catenin signaling pathway in CRC cells.


The aim of the present study was to obtain information about the experiences of Slovenian pet owners on the use of cannabidiol (CBD) products in their pets. An open online survey targeted Slovenian

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

In this in vitro study, CBD may be considered as a part of melanoma multi-drug therapy when combined with MTX.



Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells.

The results suggest that NSAID, at serum concentrations achievable in vivo, do not have direct cytotoxicity against canine tumor cells tested, and it is unlikely that the in vivo antitumor activity of NSAID is attributable to adirect cytotoxic effect.

Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.

  • C. HenryD. McCaw R. Chun
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
Mitoxantrone/piroxicam induced remission more frequently than previously reported for either drug as a single agent in this canine model of invasive human transitional cell carcinoma.

The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2

Results showed that CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF‐κB pathways with major effects in TRPV2+ cells, providing a rationale for using CBD to increase the activity of proteasome inhibitors in MM.

Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer

Cannabinoids may be an effective adjunct for the treatment of pancreatic cancer, and data on the anticancer effectiveness of various cannabinoid formulations, treatment dosing, precise mode of action, and clinical studies are lacking.

A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma

Piroxicam significantly enhanced the activity of vinblastine in dogs with UC where the cancer closely mimics the human condition, clearly justifying further study.

Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells

Results indicate that the autophagy process has a key role in CSC maintenance; inhibition of this pathway in combination with other chemotherapeutic approaches could represent a novel effective strategy to overcome drug resistance and tumor recurrence.

Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy

In this review, the role of gold nanoparticle mediated PDT combined with CBD treatment on breast cancer cells will be deliberated.

A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma

The data suggest that response to therapy as assessed by AUS or CT do not predict duration of clinical response, and CT should be considered for future clinical trials involving canine bladder TCC to improve the accuracy and repeatability of tumor measurement.

Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.

Vinblastine has antitumor activity against TCC in dogs and can be considered another treatment option for this cancer.